ACT 541468

Drug Profile

ACT 541468

Alternative Names: ACT 541468; DORA

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Sleep disorder therapies
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia

Most Recent Events

  • 03 Aug 2017 Idorsia Pharmaceuticals plans a phase III trial for Insomnia (PO)
  • 29 Jun 2017 Actelion completes a phase II trial in Insomnia (In the elderly) in USA and Germany (PO) (EudraCT2016-000827-16)
  • 20 Jun 2017 Actelion completes a phase II trial in Insomnia (In adults) in Spain, Israel, Hungary, Sweden, USA, Germany (NCT02839200)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top